Published in Drug Week, July 23rd, 2004
McMahon was named NeoRx's CEO in May 2004 and will continue to serve in that position. He succeeds Jack L. Bowman, who retired as chairman and CEO last month.
McMahon's appointment to the board increases the number of directors from six to seven.
NeoRx opened enrollment in a phase III clinical trial of skeletal targeted radiotherapy in patients with multiple myeloma in March 2004. In April 2004, NeoRx acquired the rights to develop, manufacture, and commercialize Nexplatin, a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.